Update on the review of CEP applications for sartans

18 janvier 2019

BlueRegWatch

Following new information received recently by EDQM about the presence of nitrosamine impurities in drug substances covered by certificates of suitability (CEPs), the EDQM has taken immediate actions on CEPs until appropriate corrective actions will have been implemented by the relevant company.

BlueRegWatch

Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :

Découvrez notre dernier livre blanc

En savoir plus